Print Page    Close Window

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016
DateTitle  
02/08/18Gemphire Announces Pricing of $22 Million Public Offering of Common Stock
LIVONIA, Mich., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), today announced the pricing of its previously announced underwritten public offering of 3,142,858 shares of its common stock at a public offering price of $7.00 per share. A... 
Download PDFPrinter Friendly Version
02/07/18Gemphire Announces Proposed Public Offering of Common Stock
LIVONIA, Mich., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), announced today that it has commenced an underwritten public offering of its common stock.  All shares of common stock to be sold in the offering will be offered by Gemphire... 
Download PDFPrinter Friendly Version
01/31/18Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands company’s differentiated NAFLD/NASH program across both adults and adolescents US Patent No. US 9,849,104, “Treatment of NASH with Gemcabene” issued, further enhancing intellectual property protection Company to host conference call and live webcast at 4:30 pm ET today LIVONIA, Mich., Jan. 31, 201... 
Download PDFPrinter Friendly Version
01/17/18Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients
On Track to Report Top-Line Data from Phase 2b Trial in Second Quarter of 2018 LIVONIA, Mich., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it has achieved its enrollment goal of 90 subjects across 39 sites in its Phase 2b INDIGO-1 trial investigating g... 
Download PDFPrinter Friendly Version